Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
Panacea Life Sciences Holdings, Inc. announced positive findings from an open label clinical trial on the efficacy of its CBD/CBG Oral Solution for treating irritable bowel syndrome (IBS) in adults. The study data will be published in the November 2023 issue of the American Journal of Gastroenterology and presented at the American College of Gastroenterology meeting in October 2023. The CBD/CBG tincture showed safety and efficacy in treating IBS, a condition that affects 15% of the US population. Panacea Life Sciences aims to bring cannabinoids to the forefront of natural ingredients for health and wellness.
07/20/2023 - 09:15 AM
GOLDEN, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (“Panacea” or the “Company”), a plant-based natural health and wellness company, today announced it will be presenting its positive findings from open label clinical trial on the efficacy of its CBD/CBG Oral Solution to naturally treat irritable bowel syndrome (IBS) in adults. Led by Dr. Larry Good and Dr. James Baumgartner the study data will be published in the November 2023 issue of the American Journal of Gastroenterology and presented in a poster October 23, 2023, at the American College of Gastroenterology meeting in Vancouver, Canada.
“Our research identifies the safety and efficacy of an orally administered CBD/CBG tincture in adults with active symptoms of irritable bowel syndrome. IBS affects 15% of the population of the U.S. and available conventional medical therapy is of limited efficacy. Safe and natural therapy has long been desired and sought and we are very excited about these initial results and how they can naturally help millions of people daily” said Dr. Good
Dr. James Baumgartner added, “The clinical trials and open label studies such as the one performed by Dr. Good for IBS are exactly what is required to bring CBD/CBG and the many other cannabinoids to the forefront of natural ingredients for health and wellness, managed properly.”
Since its creation, Panacea Life Sciences has been on a mission to apply cannabinoids to unmet medical needs. The Company’s continual commitment to establishing and supporting open label and clinical studies provides the foundation for discovering new and potentially safer and more effective options for treating a wide range of health conditions. The current version of Panacea’s CBD/CBG Tincture is available now at www.panacealife.com .
About Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences Holdings, Inc. (PLSH) is holding company structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural human, and animal health & wellness market segment. Its subsidiary, Panacea Life Sciences, Inc. (PLS) is a woman-founded and led company dedicated to manufacturing, distribution, research and production of the highest-quality nutraceutical, cannabinoid, mushroom, kratom and other natural, plant-based ingredients and products. PLS operates out of a 51,000 square foot, state-of-the-art, cGMP facility in Golden Colorado. If you would like more information, please visit www.panacealife.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, risks arising from supply chain disruptions or our ability to obtain raw materials as well as similar problems with our vendors, our ability to fulfill purchase orders on a timely manner, our ability to fully collect money for our purchase orders, the risk of customers returning our products, impact of the pandemic including new variants on our workforce, as well as those risks and uncertainties described by us in our annual report on Form 10-K for the fiscal year ended December 31, 2022 under the heading "Risk Factors". Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether because of new information, future developments, or otherwise, except as may be required by law.
Contact: info@panacealife.com
What did Panacea Life Sciences announce?
Panacea Life Sciences announced positive findings from an open label clinical trial on the efficacy of its CBD/CBG Oral Solution for treating irritable bowel syndrome (IBS) in adults.
Where will the study data be published?
The study data will be published in the November 2023 issue of the American Journal of Gastroenterology.
Where will the findings be presented?
The findings will be presented at the American College of Gastroenterology meeting in October 2023.
What is the prevalence of IBS in the US?
IBS affects 15% of the population of the U.S.
What is the goal of Panacea Life Sciences?
Panacea Life Sciences aims to bring cannabinoids to the forefront of natural ingredients for health and wellness.
